Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238000 | 0.92 | OPRK1 (0.30) | KDM4EMEN1ALDH1A1PKMKMT2A | |
| SCHEMBL2233832 | 0.91 | — | — | |
| SCHEMBL2236351 | 0.89 | — | — | |
| SCHEMBL2235065 | 0.89 | FPR1 (0.34) | KDM4EMEN1ALDH1A1GAAMAPT | |
| SCHEMBL2238831 | 0.88 | KDM4E (0.34) | KDM4EMEN1USP2ALDH1A1GAA | |
| SCHEMBL2234924 | 0.87 | PTGS1 (0.33) | — | |
| SCHEMBL2236199 | 0.87 | S1PR4 (0.34) | S1PR4 | |
| SCHEMBL2358402 | 0.86 | SLC9A1 (0.31) | — | |
| SCHEMBL2236798 | 0.84 | SLC9A1 (0.34) | MEN1ALDH1A1MAPTALOX12KMT2A | |
| SCHEMBL2236736 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2360163-B1 | METALLOCENE COMPLEX AND METHOD FOR POLYMERIZING OLEFIN | JAPAN POLYPROPYLENE CORP (JP) | 2014-06-25 | — | — | EP | disclosed |
| US-8461365-B2 | Metallocene complex and polymerization method of olefin | JAPAN POLYPROPYLENE CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | JAPAN POLYPROPYLENE CORPORATION (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2360163-A1 | METALLOCENE COMPLEX AND METHOD FOR POLYMERIZING OLEFIN | Japan Polypropylene Corporation (JP) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230622-A1 | METALLOCENE COMPLEX AND POLYMERIZATION METHOD OF OLEFIN | ALOX12, ALOX15, ALOX15B | S1PR4 2768/4885KDM4E 3839/4885MEN1 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.